經過評估，專家小組得出結論，在建議的使用條件下，延長低聚半乳糖在特殊醫學用途食品中的使用是安全的。部分原文報道如下：

 

　　Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the extension of use of galacto-oligosaccharides (GOS) as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF (β-GOS) is produced from milk lactose using a β-galactosidase derived from Bifidobacterium bifidum and it is proposed to be used in food for special medical purposes (FSMP). The target population is the general population from 4 years of age onwards. GOS produced according to the same production process are already authorised and included in the EU Unio n list of novel foods. The applicant stated that the maximum daily intake from the use in FSMP is 8.25 g GOS. GOS are already authorised for use in food supplements up to a daily dose of 16.2 g. FSMP co ntaining GOS are not intended to be used if food supplements co ntaining GOS are co nsumed on the same day. The information provided on the proposed use levels and anticipated intake does not raise safety concerns. The Panel co ncludes that the proposed extension of use of GOS in FSMP is safe under the proposed co nditions of use.